| Low/medium PA level | High PA level | ||||
---|---|---|---|---|---|---|
Genotype | All (n = 215) | Females (n = 82) | Males (n = 133) | All (n = 616) | Females (n = 334) | Males (n = 282) |
ACTN3 | ||||||
Total (n) | 214 | 82 | 132 | 608 | 330 | 278 |
 RR | 23.4%* | 28.0% | 20.5% | 33.4%* | 34.2% | 32.4% |
 RX | 58.9%* | 57.3% | 59.8% | 47.5%* | 47.0% | 48.2% |
 XX | 17.8% | 14.6% | 19.7% | 19.1% | 18.8% | 19.4% |
ACE | ||||||
Total (n) | 161 | 65 | 96 | 455 | 250 | 205 |
 DD | 25.5% | 29.2% | 22.9% | 24.2% | 26.4% | 21.5% |
 ID | 52.8% | 46.2% | 57.3% | 52.5% | 52.8% | 52.2% |
 II | 21.7% | 24.6% | 19.8% | 23.3% | 20.8% | 26.3% |
MAOA | ||||||
Total (n) | 187 | 70 | 117 | 534 | 290 | 244 |
 Low TA1 | 29.4% | 14.3% | 38.5% | 27.7% | 15.2% | 42.6% |
 High TA2 | 55.1% | 44.3% | 61.5% | 49.1% | 42.1% | 57.4% |
Heterozygotes3 | 15.5% | 41.4% | – | 23.2% | 42.8% | – |